# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Underweight and lowers the price target from...
Goldman Sachs analyst David Roman initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral rating and announce...
Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Hold.
At today's event, Zimmer Biomet provided its long-range plan for 2024 through 2027, including delivering: Mid-single-dig...
The partnership offers a comprehensive, turnkey solution to surgeons and institutions looking to expand their orthopedic ASC fo...
Zimmer Biomet receives an upgrade from Argus Research due to new product launches and strategic acquisitions.
Argus Research analyst David Toung upgrades Zimmer Biomet Holdings (NYSE:ZBH) from Hold to Buy and announces $150 price target.